Literature DB >> 29723411

The clinical behavior of well differentiated liposarcoma can be extremely variable: A retrospective cohort study at a major sarcoma center.

Emily Z Keung1, Naruhiko Ikoma1, Robert Benjamin2, Wei-Lien Wang3, Alexander J Lazar3, Barry W Feig1.   

Abstract

BACKGROUND: The pathogenesis of well differentiated liposarcoma (WDLPS) is poorly understood and pathologic characterization is often challenging. Descriptive terms (such as sclerosing, myxoid, inflammatory, spindle cell) are frequently encountered in the pathology reports and are of unknown clinical significance.
METHODS: Sixty-two patients with primary retroperitoneal WDLPS resected at our institution were identified (1996-2011). Pathology reports of surgical resection specimens were retrospectively reviewed and descriptive qualifiers to the WDLPS diagnosis noted.
RESULTS: Descriptive qualifiers were associated with 36 (58%) cases. WDLPS with pathologic qualifiers were more likely to be larger (median size 32 vs 25.5 cm, P = 0.01) and multifocal (36.1 vs 7.7%, P = 0.01) at diagnosis, require concomitant organ resection at surgery (50 vs 23.1%, P = 0.03), and have higher incidence of local recurrence (83.3 vs 38.5%, P < 0.01). WDLPS with pathologic qualifiers showed significantly shorter local recurrence-free survival (LRFS) and trend towards shorter distant recurrence-free survival and overall survival. Use of pathologic qualifiers with a WDLPS diagnosis independently predicted risk of worse LRFS.
CONCLUSIONS: Retroperitoneal WDLPS tumors characterized by pathologic descriptive qualifiers appear to behave more aggressively than their more typical counterparts. Further investigation is warranted to more consistently characterize and define the pathologic features commonly seen in WDLPS as these may impact patient outcomes.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  dedifferentiated; liposarcoma; retroperitoneal sarcoma; surgical resection; well differentiated

Mesh:

Year:  2018        PMID: 29723411     DOI: 10.1002/jso.25082

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum.

Authors:  John S A Chrisinger; Tariq Al-Zaid; Emily Z Keung; Cheuk Leung; Heather Y Lin; Christina L Roland; Keila E Torres; Robert S Benjamin; Davis R Ingram; Samia Khan; Neeta Somaiah; Behrang Amini; Barry W Feig; Alexander J Lazar; Wei-Lien Wang
Journal:  J Surg Oncol       Date:  2019-06-17       Impact factor: 3.454

Review 2.  Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.

Authors:  Jun Lu; David Wood; Evan Ingley; Sulev Koks; Daniel Wong
Journal:  Mol Biol Rep       Date:  2021-04-24       Impact factor: 2.316

Review 3.  Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group.

Authors:  William W Tseng; Carol J Swallow; Dirk C Strauss; Sylvie Bonvalot; Piotr Rutkowski; Samuel J Ford; Ricardo J Gonzalez; Rebecca A Gladdy; David E Gyorki; Mark Fairweather; Kyo Won Lee; Markus Albertsmeier; Winan J van Houdt; Magalie Fau; Carolyn Nessim; Giovanni Grignani; Kenneth Cardona; Vittorio Quagliuolo; Valerie Grignol; Jeffrey M Farma; Elisabetta Pennacchioli; Marco Fiore; Andrew Hayes; Dimitri Tzanis; Jacek Skoczylas; Max L Almond; John E Mullinax; Wendy Johnston; Hayden Snow; Rick L Haas; Dario Callegaro; Myles J Smith; Toufik Bouhadiba; Anant Desai; Rachel Voss; Roberta Sanfilippo; Robin L Jones; Elizabeth H Baldini; Andrew J Wagner; Charles N Catton; Silvia Stacchiotti; Khin Thway; Christina L Roland; Chandrajit P Raut; Alessandro Gronchi
Journal:  Ann Surg Oncol       Date:  2022-06-29       Impact factor: 4.339

4.  Evaluation of Efficacy of Adjuvant Radiotherapy in Well-Differentiated Liposarcoma Patients with Positive Surgical Margins: A Population-based Study.

Authors:  Haoran Wang; Boran Chen; Ying Cen; Junjie Chen
Journal:  J Oncol       Date:  2022-09-08       Impact factor: 4.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.